Medicinal Products and the Screening of Foreign Direct Investment journal article Questionable Protection of National Security Interests by Tightening Investment Control Law Kristine Plank European Pharmaceutical Law Review, Volume 5 (2021), Issue 3, Page 123 - 128 According to the European Union (EU) as well as several Member States, increased foreign direct investment (FDI) is a potential threat to public security and order. Over the past two years, numerous amendments were made to German investment control law: on the one hand, in view of the new European legal framework (‘EU Screening Regulation’) and, on the other hand, against the background of the threat that the COVID-19 pandemic posed to the supply of health commodities. This article shows which of these new rules apply to the pharmaceutical industry and offers a view on how they may affect the supply of medicines in Germany and the EU in view of their aim to protect national security interests.
Are You AI’S Favourite? EU Legal Implications of Biased AI Systems in Clinical Genetics and Genomics Anastasiya Kiseleva, Paul Quinn
A Case of Unforeseen Adverse Side-Effects? The Ireland/Northern Ireland Protocol and Medicines Regulation George Peretz, Xisca Borrás